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Sleep restriction and circadian clock disruption are associated with
metabolic disorders such as obesity, insulin resistance, and di-
abetes. The metabolic pathways involved in human sleep, however,
have yet to be investigatedwith the use of a metabolomics approach.
Here we have used untargeted and targeted liquid chromatography
(LC)/MS metabolomics to examine the effect of acute sleep depriva-
tion on plasma metabolite rhythms. Twelve healthy young male
subjects remained in controlled laboratory conditions with respect to
environmental light, sleep, meals, and posture during a 24-h wake/
sleep cycle, followed by 24 h of wakefulness. Two-hourly plasma
samples collected over the 48 h period were analyzed by LC/MS.
Principal component analysis revealed a clear time of day variation
with a significant cosine fit during the wake/sleep cycle and during
24 h of wakefulness in untargeted and targeted analysis. Of 171
metabolites quantified, daily rhythms were observed in the majority
(n = 109), with 78 of these maintaining their rhythmicity during 24 h
of wakefulness, most with reduced amplitude (n = 66). During sleep
deprivation, 27 metabolites (tryptophan, serotonin, taurine, 8 acylcar-
nitines, 13 glycerophospholipids, and 3 sphingolipids) exhibited signif-
icantly increased levels compared with during sleep. The increased
levels of serotonin, tryptophan, and taurine may explain the antide-
pressive effect of acute sleep deprivation and deserve further study.
This report, to our knowledge the first of metabolic profiling during
sleep and sleep deprivation and characterization of 24 h rhythms
under these conditions, offers a novel view of human sleep/wake
regulation.
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Circadian clocks control the timing of most daily biologicalprocesses, including cyclic changes in metabolism and the
sleep/wake cycle (1). There is a clear link between the circadian
timing system and metabolism (2–4), with disrupted circadian
rhythms, sleep restriction, and sleep deprivation associated with
metabolic disorders (obesity, insulin resistance, diabetes) and car-
diovascular disease (5–8). The underlying mechanisms linking
metabolic disease, circadian clock misalignment, and sleep re-
striction are the subject of current research, elucidation of which
will require a global “systems” approach (9). Transcriptomic studies
have shown that rhythmic gene expression may be affected by sleep
restriction, sleep deprivation, and mistimed sleep (10–12), but, as
yet, no studies have directly investigated the effect that sleep and
sleep deprivation may have on the metabolic profile. Metabolic
profiling, or “metabolomics,” is the profiling of small-molecule
metabolites and offers the potential to characterize specific meta-
bolic phenotypes associated with disrupted circadian timing and
sleep loss. Metabolomics has an advantage over other “omics”
techniques, in that it directly samples the metabolic changes in an
organism and integrates information from changes at the gene,
transcript, and protein levels, as well as posttranslational modifica-
tion (13). Additionally, metabolomics can provide insight into the
combination of genotype and environmental effects, leading to
its use in predicting responses to drugs in a “pharmacometabo-
lomic” approach (14, 15).
Daily rhythms have been identified in the metabolomes of mice
(16–18) and humans (19). Recent studies conducted in constant
routine conditions, in which the impact of exogenous factors such as
light, food, posture, and sleep are minimized, have demonstrated
endogenous circadian variation in the human metabolome (20, 21),
with one study reporting that ∼15% of the metabolites quantified in
human plasma and saliva showed circadian variation, particularly
amino acids in saliva and fatty acids in plasma (20). These human
study protocols aimed to specifically identify circadian variation in
the metabolome. However, if metabolic profiling is to be applied in
“real-life” clinical settings, and in the identification of robust bio-
markers, time-of-day variation in the human metabolome also
needs to be characterized, and the effect of sleep, wakefulness, light/
dark conditions, and meals on these daily rhythms assessed. Pre-
viously, we have characterized significant time of day variation
in ∼19% of the metabolite features detected (19). These
metabolites included corticosteroids, bilirubin, amino acids,
acylcarnitines, and lysophospholipids. Not all of these metabo-
lites, however, have been found to show circadian variation in
the constant routine studies (20), suggesting that some metabo-
lites may be affected by light/dark, sleep/wake, or food.
Significance
Sleep restriction and circadian clock disruption are associated
with metabolic disorders including obesity and diabetes; this
association can be studied by using the powerful tool of
metabolomics. By using liquid chromatography/MS metab-
olomics, we have characterized plasma metabolites that were
significantly affected by acute sleep deprivation (mainly lipids
and acylcarnitines), all increasing during sleep deprivation.
Observed increased levels of serotonin, tryptophan, and tau-
rine may explain the antidepressive effect of sleep deprivation
and deserve further study. Clear daily rhythms were observed
in most metabolites, with 24 h wakefulness mainly reducing
the amplitude of these rhythms. Our results further the un-
derstanding of sleep/wake regulation and the associated
metabolic processes, and will be vital when using metabolic
profiling to identify robust biomarkers for disease states and
drug efficacy.
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The two-process model of sleep regulation proposes that sleep
is driven by a homeostatic component (i.e., process S) and an
endogenous circadian oscillator (i.e., process C) (22). The link
between the homeostatic and circadian regulation of sleep and
metabolic pathways remains ill-defined. Sleep restriction or total
sleep deprivation has been shown to reduce the number and the
amplitude of genes exhibiting circadian rhythmicity (10, 11, 23).
The expression of genes affected by sleep restriction included
circadian clock and sleep homeostasis genes, as well those as-
sociated with oxidative stress and metabolism. How these changes
in the transcriptome translate into changes in the metabolome,
however, remains unknown.
Metabolomics can be used not only to study homeostatic regu-
lation but also system perturbations. The metabolic pathways in-
volved in human sleep and during sleep deprivation have not yet
been systematically studied by using a metabolomics approach.
Since 24 h sleep deprivation primarily affects the homeostatic reg-
ulator of sleep, acute total sleep deprivation permits assessment of
the metabolic basis of this homeostatic process. The aim of the
present study was thus to characterize plasma metabolite rhythms
using untargeted and targeted liquid chromatography (LC)/MS
metabolomics in healthy male participants during a 24 h wake/
sleep cycle followed by 24 h of wakefulness.
Results
All participants had a melatonin onset time within a similar
range (mean ± SEM, 21:47 ± 0:35 h, day 1, wake/sleep), and this
did not change significantly between study days (21:58 ± 0:31 h,
day 2, wake/wake). Levels of melatonin were significantly in-
creased (27 ± 5%) during sleep deprivation [00:00–06:00 h, night
2 (N2)] compared with during sleep [00:00–06:00 h, night 1 (N1);
P < 0.005; SI Appendix, Fig. S1].
By using the untargeted LC/MS metabolomics method de-
scribed, we extracted 367 metabolite features for each sample. A
principal component analysis (PCA) of all data showed there was
clear time-of-day variation in the metabolome in principal
component (PC) 1 [amount of variance in the x matrix explained
by PC1 (R2) = 0.145, estimate of the predictive ability of the
model (Q2) (cumulative) = 0.437; Fig. 1A], with the mean score
on PC1 having a significant fit to a cosine curve on day 1 (wake/
sleep) and day 2 (wake/wake). There was a 14% reduction in
cosinor amplitude from day 1 (wake/sleep) to day 2 (wake/wake).
Orthogonal partial least squares discriminant analysis (OPLS-
DA) models, validated by permutation analysis, showed some
separation between sleep (00:00–06:00 h day 1) and sleep dep-
rivation periods [00:00–06:00 h day 2; Q2 (cumulative) = 0.0692,
total amount of variance explained in the x matrix (R2X) (cu-
mulative) = 0.188, total amount of variance explained in the y
matrix (R2Y) (cumulative) = 0.546; Fig. 1B], and clear separa-
tion with time of day (14:00–18:00 h vs. 02:00–06:00 h) on day 1
[Q2 (cumulative) = 0.546, R2X (cumulative) = 0.262, R2Y (cu-
mulative) = 0.886; Fig. 1C] and day 2 [Q2 (cumulative) = 0.604,
R2X (cumulative) = 0.250, R2Y (cumulative) = 0.867; Fig. 1D].
From the 367 features, we identified metabolites includ-
ing acylcarnitines, lysophospholipids, phosphocholines, amino
acids, cortisol, and bilirubin by using our previously published
masses and fragments (19) [intraassay quality control (QC) coef-
ficient of variation (CV), 25 ± 3%]. Eight acylcarnitines [pro-
pionylcarnitine (C3:0), octenoylcarnitine (C8:1), decanoylcarnitine
(C10:0), dodecanoylcarnitine (C12:0), tetradecanoylcarnitine (C14:0),
tetradenenoylcarnitine (C14:1), tetradecadienoylcarnitine (C14:2),
hexadecanoylcarnitine (C16:0)] of the 14 identified were found to
have significantly different levels between sleep (00:00–06:00 h, day 1)
and sleep deprivation (00:00–06:00 h, day 2). All but octenoylcarni-
tine (C8:1) were increased during sleep deprivation compared with
during sleep. As many of the metabolite classes identified using
our established LC/MS methodology could also be measured
using the Biocrates AbsoluteIDQ p180 targeted metabolomics
kit, we elected to run duplicate samples using the AbsoluteIDQ
p180 kit to increase the number of metabolites screened (n = 171)
and to be able to measure absolute metabolite concentrations against
validated standards. In a PCA of all targeted metabolomic analysis
data, there was clear time-of-day variation in the metabolome in
principal component 1 [R2 (PC1) = 0.364, Q2 (cumulative) =
0.768; Fig. 1E], with the mean score on PC1 having a significant
fit to a cosine curve on day 1 (wake/sleep) and day 2 (wake/
wake). There was a 24% reduction in cosinor amplitude from
day 1 to day 2. OPLS-DA models, validated by permutation
analysis, showed clear separation between sleep (00:00–06:00 h,
day 1) and sleep deprivation [(00:00–06:00 h, day 2; Q2 (cumu-
lative) = 0.746, R2X (cumulative) = 0.635, R2Y (cumulative) =
0.892; Fig. 1F], and clear separation with time of day (14:00–18:00 h
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Fig. 1. Multivariate analysis of untargeted (A–D) and targeted (E–H) metabolomics data. (A and E) PCA of all analysis data were carried out, and the change
in mean score (±SEM) across all subjects on PC1 with time is shown (A, untargeted; E, targeted). White bars, awake, 90 lx, free to move; gray bars, awake,
<5 lx, semirecumbent; black bars, sleeping with eye masks, 0 lx, supine. (B and F) OPLS-DA models separating selected time points according to sleep status
(B, untargeted; F, targeted); black circles, sleep, day 1 00:00–06:00 h; red diamonds, sleep deprivation, day 2 00:00–06:00 h). (C, D, G, and H) OPLS-DA models
(validated by permutation analysis) in which selected time periods were classed according to time of day (blue circles, 02:00–06:00 h; orange triangles, 14:00–
18:00 h). This analysis was carried out for day 1 (C, untargeted; G, targeted) and day 2 (D, untargeted; H, targeted).
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vs. 02:00–06:00 h) on day 1 [Q2 (cumulative) = 0.830, R2X
(cumulative) = 0.555, R2Y (cumulative) = 0.920; Fig. 1G] and
day 2 [Q2 (cumulative) = 0.825, R2X (cumulative) = 0.530, R2Y
(cumulative) = 0.913; Fig. 1H]. The p(corr) values for each
OPLS-DA model are given in SI Appendix, Table S2. For com-
pleteness, OPLS-DA models of selected time windows across
the 24 h period were generated. These OPLS-DA plots and the
p(corr) values for each OPLS-DA model are presented in SI
Appendix, Fig. S2 and Table S3, respectively.
Metabolites showing significant differences (P < 0.05 and q <
0.05) across selected time periods, time of day, and selected time
period-by-time of day interaction are shown in SI Appendix,
Table S4. As expected, most significant differences in metabolite
levels were observed in the time of day grouping (range, 59–159
of 171). Looking at selected time periods across the protocol,
comparison between the sleep and sleep deprivation period
revealed the most significant differences (n = 41) compared with
the other time periods (range, 0–21). A Venn diagram showing
the number of metabolites that were significantly different be-
tween the sleep and sleep-deprivation time periods (00:00–06:00 h),
time of day, and interaction, as well as the overlap, is pre-
sented in SI Appendix, Fig. S3. Of the total 171 metabolites
quantified, 41 metabolites exhibited significant changes (P <
0.05, q < 0.05) during sleep deprivation compared with during
sleep. All these metabolites (n = 41) exhibited increased levels
during sleep deprivation. The percent changes between sleep
and sleep deprivation for these metabolites is presented in SI
Appendix, Table S5, with serotonin showing the largest change
(44 ± 20%) between the two conditions. Full 48-h profiles of
these metabolites are presented in Fig. 2 and are annotated in
bold in SI Appendix, Tables S6 and S7. The metabolites showing
significantly increased levels during sleep deprivation come from
a range of classes (25 glycerophospholipids, 9 acylcarnitines,
4 sphingolipids, 2 biogenic amines, 1 amino acid). Most of these
metabolites (n = 27; 66%) only increased significantly (P < 0.05,
q < 0.05) during sleep deprivation compared with during sleep
(annotated in Fig. 2). These metabolites comprised the amino acid,
tryptophan, biogenic amines, serotonin, and taurine, eight acylcar-
nitines [propionylcarnitine (C3), valerylcarnitine (C5), octa-
noylcarnitine (C8), nonaylcarnitine (C9), decanoylcarnitine
(C10), dodecanoylcarnitine (C12), tetradecanoylcarnitine (C14),
hydroxyhexadecadienylcarnitine (C16:2-OH)], 13 glycerophos-
pholipids, and three sphingolipids. Overrepresentation analysis
has been performed with the IMPaLA Web tool (http://impala.
molgen.mpg.de) using these 27 metabolites significantly increased
in sleep deprivation (dataset of interest) and all 171 metabolites
identified by using targeted analysis (background dataset; SI
Appendix, Results and Discussion). The remaining metabolites
(n = 14; 34%), in addition to increasing between the sleep/sleep
deprivation conditions, also changed significantly (P < 0.05, q <
0.05) between the wake conditions (14:00–22:00 h on day 1 and
day 2). These were predominately glycerophospholipids (n = 12,
86%) as well as one acylcarnitine (pimelylcarnitine, C7-DC) and
one sphingolipid [SM (OH) C16:1].
The mean (±SEM) concentration and minimum and maximum
concentrations measured for each metabolite is presented in SI
Appendix, Table S7. To assess rhythmic variation of the quantified
metabolites, cosinor analysis was performed. Fig. 3 presents the
number of rhythmic metabolites in the sleep/wake and wake/wake
conditions and the classes to which these metabolites belong. Of the
171 metabolites, 109 (64%) exhibited a diurnal rhythm that had
a significant fit to a cosine curve on day 1 (wake/sleep), the levels of
most (n = 95; 87%) peaking during the day (06:00–18:00 h). Of
those with daily rhythms, most (n = 78; 72%) maintained their
rhythmicity on day 2 during the 24 h of wakefulness. These included
four of the nine biogenic amines measured (α-aminoadipic acid,
symmetrical dimethylarginine, kynurenine, sarcosine), 11 of the 40
acetylcarnitines, 45 of the 86 glycerophospholipids, and 13 of the 14
sphingolipids. Amino acids with significant 24 h rhythms irrespective
of the presence or absence of sleep included the branched chain
amino acids (BCAAs) isoleucine and valine, glutamate, ornithine,
and proline, all peaking at night between 21.28 and 01.45 decimal h
on day 1. The metabolites that lost their rhythmicity on day 2 (wake/
wake; n = 31, 28%) were 14 acylcarnitines, 13 glycerophospholipids,
one sphingolipid [SM (OH) C14:1], hexose, total dimethylarginine,
and taurine. A few metabolites (n = 15, 9%) did not exhibit a sig-
nificant cosine rhythm on day 1 but did on day 2. These included 11
glycerophospholipids, 2 acylcarnitines, tyrosine, and aspartate. A
heat map of the metabolites that showed significant cosinor rhythms
on day 1 (n = 31), day 2 (n = 15), or both day 1 and day 2 (n = 78) is
presented in SI Appendix, Fig. S4. The 47 remaining metabolites
(28%) that had no significant cosinor rhythm on either day com-
prised 17 glycerophospholipids, 14 amino acids, 13 acylcarnitines,
and 3 biogenic amines (Fig. 3). The results of the cosinor analysis
for all 171 metabolites (amplitude, acrophase, P value) are given in
SI Appendix, Table S6. A change in acrophase and amplitude be-
tween day 1 and day 2 was calculated for the 78 metabolites with
significant fits to a cosine curve on day 1 and day 2. The mean
phase shift (±SEM) between day 1 and day 2 was an advance of
0.67 ± 0.14 h. The majority of these metabolites (n = 66; 85%)
exhibited reduced amplitude during 24 h of wakefulness. For the
metabolites that peaked during the day (n = 67; 86%), most (n =
63; 94%) exhibited a reduction in amplitude during the 24 h of
wakefulness. On the contrary, for those metabolites that peaked
during the night (n = 11; 14%), 24 h of wakefulness increased the
amplitude of the cosinor rhythm in most cases (n = 8; 73%; SI
Appendix, Table S6).
Discussion
To our knowledge, this is the first report of metabolic profiling
during sleep and acute total sleep deprivation conditions in
humans. Characterizing the 24-h rhythms in plasma metabolites
under these conditions by using LC/MS metabolomics offers a
unique view of sleep processing and sleep/wake regulation.
A consistent finding in the untargeted and targeted analysis
was that, in comparison with the number of ions and metabolites
showing time-of-day rhythms, fewer ions/metabolites were sig-
nificantly changed during sleep deprivation. In the targeted
analysis, only 27 of the measured metabolites (16%) were sig-
nificantly different between the sleep and sleep-deprivation
periods without exhibiting differences during the two wake
conditions. All these metabolites (serotonin, taurine, tryptophan,
8 acylcarnitines, 13 glycerophospholipids, 3 sphingolipids) increased
during the sleep-deprivation period. It may be that sleep has an
inhibitory effect on their synthesis or a stimulatory effect on their
degradation. A single metabolomics study attempting to identify the
pathways activated by waking in mice also showed that relatively
few metabolite pathways were affected by 6 h of sleep deprivation,
including glycolysis and lipid metabolism (24). Both in vivo after
sleep deprivation and in vitro following stimulation of cortical cul-
tures, increased levels of lysolipids were measured, suggesting that
sleep may be involved in neuronal membrane homeostasis.
Serotonin is one of several neurotransmitters involved in sleep/
wake regulation, functioning primarily to promote wakefulness (25).
The increased plasma concentrations observed in the present study
support previous studies in which higher serotonin levels have been
measured in the hippocampus, dorsal raphe, and suprachiasmatic
nuclei (SCN) of sleep-deprived rats (26, 27). The antidepressive
effect of one night of total sleep deprivation is well established (28,
29), although the mechanism of action of this intervention remains
undefined. Given that low levels of serotonin and reduced seroto-
ninergic neurotransmission have long been associated with major
depressive disorder (30), and the related efficacy of selective sero-
tonin reuptake inhibitors in this illness (30, 31), the raised levels of
serotonin we observed during sleep deprivation may provide a pos-
sible antidepressive mechanism for this intervention in humans. It
also supports recent human in vivo evidence showing increased ce-
rebral serotonin 2A receptor binding during 24 h of wakefulness (32).
Of the 21 amino acids quantified in the targeted analysis, only
tryptophan was found to vary significantly with sleep status, with
increased levels during acute sleep deprivation. Tryptophan is vital
for the formation of serotonin and melatonin via the indoleamine
Davies et al. PNAS | July 22, 2014 | vol. 111 | no. 29 | 10763
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pathway. Tryptophan itself, as well as 5-hydroxytryptophan, an
intermediate in the indoleamine pathway, has also been used to
treat depressive disorder (33, 34). The increased levels of trypto-
phan measured during sleep deprivation may contribute to the
antidepressive effect of sleep deprivation, directly or indirectly via
serotonin synthesis. The biogenic amine taurine also exhibited sig-
nificantly increased levels during sleep deprivation compared with
during sleep. Increased levels of taurine have been reported in the
rat brain cortex following paradoxical sleep deprivation (35) and
have been shown to be a activator of extrasynaptic GABA(A)
receptors in the mouse ventrobasal thalamus (36), an area involved
in regulating the transitions between sleep and wakefulness (37).
Taurine has also been found at altered levels in the plasma of
depressed patients, at increased concentrations in some cases (38),
and at lower concentrations compared with controls in others (39).
It remains intriguing that the only amino acid and biogenic
amines shown here to increase during acute sleep deprivation
(serotonin, tryptophan, taurine) have been implicated in the
etiology of depression (30, 33, 34, 38, 39). In addition, all three
metabolites have relatively high concentrations in the pineal
gland (40, 41). The pineal hormone melatonin was also measured in
the present and previous study (11), with significantly increased
plasma concentrations being observed during sleep deprivation.
Increased tryptophan and taurine could explain the increased
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Fig. 2. Concentrations of 41 individual metabolites (z-score mean ± SEM) found at significantly higher levels (P < 0.05, q < 0.05) during sleep deprivation
compared with during sleep (00:00–06:00 h). Asterisks and bold labels denote metabolites only showing significant changes between the sleep and sleep-
deprivation (00:00–06:00 h) conditions. The metabolites not annotated also changed significantly (P < 0.05, q < 0.05) between wake periods (14:00–22:00 h)
on day 1 and day 2. White bars, awake, 90 lx, free to move; gray bars, awake, < 5 lx, semirecumbent; black bars, sleeping with eye masks, 0 lx, supine.
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melatonin levels, as taurine has been shown to increase pineal
melatonin by stimulating the activity of its rate limiting biosynthetic
enzyme,N-acetyltransferase (42). Whether the antidepressive effect
of acute sleep deprivation is linked to the increased circulating
levels of tryptophan, serotonin, taurine, and melatonin deserves
further study. In addition, whether acute sleep deprivation activates
the SCN–pineal pathway requires clarification.
Levels of glycerophospholipids (25 of 86, 29%) and sphingolipids
(4 of 14, 29%) also significantly increased during sleep deprivation
compared with sleep. However, some of these glycerophospholipids
(12 of 25) and sphingolipids (1 of 4) also increased significantly
during the wake period on day 2 compared with day 1. This steady
increase in circulating glycerophospholipids and sphingolipids
across the study period confounds any sleep/sleep deprivation
analysis. The food content at each set meal was identical, and
thus diet is unlikely to explain the findings. Although the par-
ticipants were free to move during some of the wake period,
inactivity and lack of exercise during the laboratory study pro-
tocol may explain this accumulation. A buildup of some metab-
olites has previously been observed during a constant routine
protocol (20). Despite the accumulation of glycerophospholipids
and sphingolipids during the study protocol, most of the glycer-
ophospholipids and sphingolipids quantified here exhibited a
significant fit to a cosine curve regardless of sleep status and
meal pulses. This finding is consistent with the idea that the
endogenous circadian system controls lipid metabolism (43) and
with previous human metabolomics and transcriptomic studies
examining circadian variation (20, 21, 23) (SI Appendix, Results
and Discussion). Transcriptomic data (12) also support the me-
tabolomics data showing that transcripts associated with lipid
metabolism are robustly rhythmic, and are not affected by
mistimed sleep.
During sleep deprivation, nine acylcarnitines had significantly
increased levels compared with during the sleep period. Most of
these acylcarnitines (eight of nine) were significantly increased
only during sleep deprivation compared with sleep, not between
the wake conditions, suggesting an effect of high sleep pressure
on acylcarnitine levels. These affected acylcarnitines were medium-
and long-chain saturated acylcarnitines (C3, C5, C8, C9, C10, C12,
C14, and C16:2-OH), pointing to possible changes in β-oxidation
of fatty acids during sleep deprivation. The increased plasma
3-hydroxydecanoate, an intermediate in the β-oxidation of fatty
acids, observed by Dallmann et al. (20) during 40 h of continual
wakefulness, supports this hypothesis. Our findings support reports
indicating a role for the carnitine system and fatty acid oxidation in
sleep/wake regulation. Acylcarnitine levels have been reported to
be low, and carnitine palmitoyltransferase 1B expression, the rate-
limiting enzyme in the β-oxidation of long-chain fatty acids, has
been reported to be significantly higher in patients with narcolepsy
than in control subjects (44). Oral L-carnitine was recently tested
in patients with narcolepsy and shown to reduce their excessive
daytime sleepiness (45). Similarly low serum acylcarnitine levels
have been measured in patients with chronic fatigue syndrome
(46), another condition with reported sleep problems (47), and
L-carnitine administration has also shown some benefit in re-
ducing fatigue (48). These studies support the growing evidence
from mutant mice studies that altered fatty acid metabolism affects
sleep signaling (49). The mechanism underlying these observed
changes (e.g., sympathetic tone and lipolysis or mitochondrial
function and fatty acid oxidation) and their source (liver, skeletal
muscle, fat) require further study.
The present study protocol was also designed to be able to
assess the effect of 24 h wakefulness on the daily metabolite
rhythms observed in a regular sleep/wake cycle. When all
metabolites were considered simultaneously, PCA revealed
a clear time-of-day variation with a significant fit to a cosine
curve during a wake/sleep cycle and during 24 h of wakefulness
in untargeted and targeted analysis. Cosinor analysis of the in-
dividual plasma metabolites identified by the targeted screens
(n = 171) demonstrated robust daily rhythms in the majority of
metabolites, confirming and extending the findings from pre-
vious human diurnal and circadian metabolomics studies (19–21)
(SI Appendix, Results and Discussion). The overall effect of 24 h
wakefulness on the PCA-derived daily wake/sleep rhythm was a re-
duction in amplitude in the untargeted and targeted analysis, which
is consistent with reported transcriptomic sleep deprivation data
(11, 23). In the targeted screens (n = 171), of the 109 metabolites
that exhibited significant fits to a cosine curve during wake/sleep,
the majority (72%) maintained their rhythmicity during the 24 h of
wakefulness. Metabolites that peaked during the day predominately
showed reduced amplitude during the 24 h wake period, whereas
metabolites that peaked during the night showed increased ampli-
tude. These time-specific changes in amplitude are consistent with
increased levels of metabolites during sleep deprivation.
Of the 40 acylcarnitines quantified with targeted analysis, 63%
were shown to vary significantly with time of day on day 1 (wake/
sleep), and 56% retained this rhythmicity during sleep depriva-
tion. The daily rhythms in acylcarnitines support previous studies
(19, 20) (SI Appendix, Results and Discussion) and gene expres-
sion data, with key transporters of long-chain acylcarnitines
exhibiting clear oscillation with time of day in mice (50).
Most of the amino acids (76%) did not vary significantly with
time of day, possibly reflecting the effect of the timed meals on
these amino acid profiles (51). However, glutamate, ornithine,
proline, and two of the BCAAs, isoleucine and valine, had 24-h
rhythms with significant fits to a cosine curve, irrespective of the
presence or absence of sleep or meals, with levels peaking at
night (between 21:00 and 01:30 h). Knowledge of this daily
variation in isoleucine and valine may aid in optimizing their
therapeutic efficacy, for example, to improve protein metabolism
in patients with liver cirrhosis, in whom administration of BCAAs
at night is known to be more effective than during the day (52).
Further characterization of the endogenous fluctuations of
metabolites such as BCAAs under different conditions (e.g., in
type 2 diabetes) may help to generate testable hypotheses relating
to the best time of day to administer treatments most effectively.
The present study assessed metabolite profiles during a single
night of total sleep deprivation with the aim of characterizing the
effect of increased sleep pressure on metabolite levels as well
as investigating the masking effect of sleep on daily metabolite
rhythms. Acute total sleep deprivation, in addition to permitting in-
vestigation of the homeostatic sleep drive, also mimics the first night
of night shift work and one methodology of antidepressive therapy
used in psychiatry (28, 29). The protocol, however, does not allow
identification of metabolites that might only be affected by pro-
longed, repeated sleep deprivation; the metabolic changes observed
under chronic partial sleep deprivation remain to be determined.
In conclusion, we have identified plasma metabolites that were
significantly altered during acute sleep deprivation (mainly lipids
and acylcarnitines, serotonin, tryptophan, and taurine), all increasing
during sleep deprivation. The 24-h variation in several metabolite
classes (amino acids, biogenic amines, acylcarnitines, glycer-
ophospholipids, sphingolipids) has also been characterized in the
Biogenic amines
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Sphingolipids
Amino acids
31 1578 47
A
B C D E
Fig. 3. (A) Venn diagram showing the number of metabolites exhibiting
a significant fit to a cosine curve on day 1 (left circle, blue), day 2 (right circle,
yellow), both days (n = 78), or neither (n = 47). (B–E) Pie charts showing the
proportion of metabolites from each metabolite class [exhibiting a signifi-
cant fit to a cosine curve on day 1 only (B), on days 1 and day 2 (C), on day 2
only (D), and on neither day (E)].
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presence and absence of a night’s sleep. Determining the full
impact of exogenous factors such as sleep on the metabolome
will be crucial for the future metabolic profiling-based identifi-
cation of biomarkers of disease and drug effects. In addition, this
metabolomics approach is a step toward understanding sleep/
wake regulation and the associated metabolic pathways involved
in these processes.
Materials and Methods
Clinical Study. The study was approved by the University of Surrey Ethics
Committee and conducted according to the Declaration of Helsinki. Subjects
had to meet defined inclusion/exclusion criteria to be deemed eligible for the
study (SI Appendix, Materials and Methods).
In-Laboratory Session. The 4-d in-laboratory session was conducted at the
Surrey Clinical Research Centre and consisted of an adaptation night fol-
lowed by a 48-h sampling period beginning at 12:00 h, which comprised
a 24-h period (day 1) incorporating an 8-h sleep opportunity (23:00–07:00 h;
N1), followed by 24 h (beginning at 12:00 h, day 2) during which subjects
remained continually awake (day 2/N2; SI Appendix, Fig. S5). Blood samples
were collected for 48 h at hourly and 2-hourly intervals from 12:00 h on day
1 for melatonin and LC/MS analysis, respectively (SI Appendix, Materials
and Methods).
Metabolomic Analysis. Details of the untargeted and targeted metabolomics
analysis, as well as all statistical analyses, are given in SI Appendix, Materials
and Methods.
ACKNOWLEDGMENTS. The authors thank Daniel Barrett, Cheryl Isher-
wood, and the Surrey Clinical Research Centre medical, clinical, and
research teams for their help with the clinical study. This work was
supported in part by the Netherlands Forensic Institute, Netherlands
Genomics Initiative/Netherlands Organization for Scientific Research
within the framework of the Forensic Genomics Consortium Nether-
lands, the 6th Framework project EUCLOCK (018741), and UK Biotechnol-
ogy and Biological Sciences Research Council Grant BB/I019405/1. D.J.S. is
a Royal Society Wolfson Research Merit Award holder.
1. Mohawk JA, Green CB, Takahashi JS (2012) Central and peripheral circadian clocks in
mammals. Annu Rev Neurosci 35:445–462.
2. Green CB, Takahashi JS, Bass J (2008) The meter of metabolism. Cell 134(5):728–742.
3. Bass J, Takahashi JS (2010) Circadian integration of metabolism and energetics. Sci-
ence 330(6009):1349–1354.
4. Eckel-Mahan K, Sassone-Corsi P (2013) Metabolism and the circadian clock converge.
Physiol Rev 93(1):107–135.
5. Bass J, Turek FW (2005) Sleepless in America: A pathway to obesity and the metabolic
syndrome? Arch Intern Med 165(1):15–16.
6. Spiegel K, Knutson K, Leproult R, Tasali E, Van Cauter E (2005) Sleep loss: A novel risk
factor for insulin resistance and type 2 diabetes. J Appl Physiol (1985) 99(5):
2008–2019.
7. Scheer FA, Hilton MF, Mantzoros CS, Shea SA (2009) Adverse metabolic and cardio-
vascular consequences of circadian misalignment. Proc Natl Acad Sci USA 106(11):
4453–4458.
8. Cappuccio FP, Cooper D, D’Elia L, Strazzullo P, Miller MA (2011) Sleep duration pre-
dicts cardiovascular outcomes: A systematic review and meta-analysis of prospective
studies. Eur Heart J 32(12):1484–1492.
9. Rey G, Reddy AB (2013) Connecting cellular metabolism to circadian clocks. Trends
Cell Biol 23(5):234–241.
10. Maret S, et al. (2007) Homer1a is a core brain molecular correlate of sleep loss. Proc
Natl Acad Sci USA 104(50):20090–20095.
11. Ackermann K, et al. (2013) Effect of sleep deprivation on rhythms of clock gene ex-
pression and melatonin in humans. Chronobiol Int 30(7):901–909.
12. Archer SN, et al. (2014) Mistimed sleep disrupts circadian regulation of the human
transcriptome. Proc Natl Acad Sci USA 111(6):E682–E691.
13. Raamsdonk LM, et al. (2001) A functional genomics strategy that uses metabolome
data to reveal the phenotype of silent mutations. Nat Biotechnol 19(1):45–50.
14. Clayton TA, et al. (2006) Pharmaco-metabonomic phenotyping and personalized drug
treatment. Nature 440(7087):1073–1077.
15. Holmes E, Wilson ID, Nicholson JK (2008) Metabolic phenotyping in health and dis-
ease. Cell 134(5):714–717.
16. Minami Y, et al. (2009) Measurement of internal body time by blood metabolomics.
Proc Natl Acad Sci USA 106(24):9890–9895.
17. Fustin JM, et al. (2012) Rhythmic nucleotide synthesis in the liver: Temporal segre-
gation of metabolites. Cell Reports 1(4):341–349.
18. Eckel-Mahan KL, et al. (2012) Coordination of the transcriptome and metabolome by
the circadian clock. Proc Natl Acad Sci USA 109(14):5541–5546.
19. Ang JE, et al. (2012) Identification of human plasma metabolites exhibiting time-of-
day variation using an untargeted liquid chromatography-mass spectrometry me-
tabolomic approach. Chronobiol Int 29(7):868–881.
20. Dallmann R, Viola AU, Tarokh L, Cajochen C, Brown SA (2012) The human circadian
metabolome. Proc Natl Acad Sci USA 109(7):2625–2629.
21. Kasukawa T, et al. (2012) Human blood metabolite timetable indicates internal body
time. Proc Natl Acad Sci USA 109(37):15036–15041.
22. Borbély AA (1982) A two process model of sleep regulation. Hum Neurobiol 1(3):
195–204.
23. Möller-Levet CS, et al. (2013) Effects of insufficient sleep on circadian rhythmicity and
expression amplitude of the human blood transcriptome. Proc Natl Acad Sci USA
110(12):E1132–E1141.
24. Hinard V, et al. (2012) Key electrophysiological, molecular, and metabolic signatures
of sleep and wakefulness revealed in primary cortical cultures. J Neurosci 32(36):
12506–12517.
25. Monti JM (2011) Serotonin control of sleep-wake behavior. Sleep Med Rev 15(4):
269–281.
26. Peñalva RG, et al. (2003) Effect of sleep and sleep deprivation on serotonergic neu-
rotransmission in the hippocampus: A combined in vivo microdialysis/EEG study in
rats. Eur J Neurosci 17(9):1896–1906.
27. Alfaro-Rodríguez A, González-Piña R, González-Maciel A, Arch-Tirado E (2006) Serotonin
and 5-hydroxy-indole-acetic acid contents in dorsal raphe and suprachiasmatic nuclei
in normal, malnourished and rehabilitated rats under 24 h of sleep deprivation. Brain Res
1110(1):95–101.
28. Wu JC, Bunney WE (1990) The biological basis of an antidepressant response to sleep
deprivation and relapse: review and hypothesis. Am J Psychiatry 147(1):14–21.
29. Wirz-Justice A, Van den Hoofdakker RH (1999) Sleep deprivation in depression: What
do we know, where do we go? Biol Psychiatry 46(4):445–453.
30. Ressler KJ, Nemeroff CB (2000) Role of serotonergic and noradrenergic systems in the
pathophysiology of depression and anxiety disorders. Depress Anxiety 12(suppl 1):2–19.
31. Vaswani M, Linda FK, Ramesh S (2003) Role of selective serotonin reuptake inhibitors
in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol
Psychiatry 27(1):85–102.
32. Elmenhorst D, Kroll T, Matusch A, Bauer A (2012) Sleep deprivation increases cerebral
serotonin 2A receptor binding in humans. Sleep 35(12):1615–1623.
33. Coppen A, Noguera R (1970) L-tryptophan in depression. Lancet 1(7656):1111.
34. Turner EH, Loftis JM, Blackwell AD (2006) Serotonin a la carte: Supplementation with
the serotonin precursor 5-hydroxytryptophan. Pharmacol Ther 109(3):325–338.
35. Mohammed HS, Aboul Ezz HS, Khadrawy YA, Noor NA (2011) Neurochemical and
electrophysiological changes induced by paradoxical sleep deprivation in rats. Behav
Brain Res 225(1):39–46.
36. Jia F, et al. (2008) Taurine is a potent activator of extrasynaptic GABA(A) receptors in
the thalamus. J Neurosci 28(1):106–115.
37. Coulon P, Budde T, Pape H-C (2012) The sleep relay—the role of the thalamus in
central and decentral sleep regulation. Pflugers Arch 463(1):53–71.
38. Altamura C, Maes M, Dai J, Meltzer HY (1995) Plasma concentrations of excitatory
amino acids, serine, glycine, taurine and histidine in major depression. Eur Neuro-
psychopharmacol 5(suppl):71–75.
39. Perry TL, et al. (1975) Hereditary mental depression and Parkinsonism with taurine
deficiency. Arch Neurol 32(2):108–113.
40. Quay WB (1963) Circadian rhythm in rat pineal serotonin and its modifications by
estrous cycle and photoperiod. Gen Comp Endocrinol 14:473–479.
41. Vellan EJ, Gjessing LR, Stalsberg H (1970) Free amino acids in the pineal and pituitary
glands of human brain. J Neurochem 17(5):699–701.
42. Wheler GH, Weller JL, Klein DC (1979) Taurine: stimulation of pineal N-acetyl-
transferase activity and melatonin production via a beta-adrenergic mechanism.
Brain Res 166(1):65–74.
43. Huang W, Ramsey KM, Marcheva B, Bass J (2011) Circadian rhythms, sleep, and me-
tabolism. J Clin Invest 121(6):2133–2141.
44. Miyagawa T, et al. (2011) Abnormally low serum acylcarnitine levels in narcolepsy
patients. Sleep 34(3):349–53A.
45. Miyagawa T, et al. (2013) Effects of oral L-carnitine administration in narcolepsy
patients: A randomized, double-blind, cross-over and placebo-controlled trial. PLoS
ONE 8(1):e53707.
46. Kuratsune H, et al. (1998) Low levels of serum acylcarnitine in chronic fatigue syn-
drome and chronic hepatitis type C, but not seen in other diseases. Int J Mol Med 2(1):
51–56.
47. Fukuda K, et al.; International Chronic Fatigue Syndrome Study Group (1994) The
chronic fatigue syndrome: A comprehensive approach to its definition and study. Ann
Intern Med 121(12):953–959.
48. Plioplys AV, Plioplys S (1997) Amantadine and l-carnitine treatment of chronic fatigue
syndrome. Neuropsychobiology 35(1):16–23.
49. Tafti M, et al. (2003) Deficiency in short-chain fatty acid β-oxidation affects theta
oscillations during sleep. Nat Genet 34(3):320–325.
50. Hughes ME, et al. (2009) Harmonics of circadian gene transcription in mammals. PLoS
Genet 5(4):e1000442.
51. Ashley DV, Barclay DV, Chauffard FA, Moennoz D, Leathwood PD (1982) Plasma
amino acid responses in humans to evening meals of differing nutritional composi-
tion. Am J Clin Nutr 36(1):143–153.
52. Fukushima H, et al. (2003) Nocturnal branched-chain amino acid administration im-
proves protein metabolism in patients with liver cirrhosis: comparison with daytime
administration. JPEN J Parenter Enteral Nutr 27(5):315–322.
10766 | www.pnas.org/cgi/doi/10.1073/pnas.1402663111 Davies et al.
